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Marine lipopeptide Iturin A inhibits 
Akt mediated GSK3β and FoxO3a 
signaling and triggers apoptosis in 
breast cancer
Goutam Dey1, Rashmi Bharti1, Gunaseelan Dhanarajan2, Subhasis Das1, 
Kaushik Kumar Dey1, B N Prashanth  Kumar1, Ramkrishna Sen2 & Mahitosh Mandal1
Akt kinase is a critical component of the PI3K/Akt signaling pathway, which is frequently over 
expressed in human cancers including breast. Therapeutic regimens for inhibiting breast cancer with 
aberrant Akt activity are essential. Here, we evaluated antitumor effect of a marine bacteria derived 
lipopeptide ‘Iturin A’ on human breast cancer in vitro and in vivo through disrupting Akt pathway. 
Proliferation of MDA-MB-231 and MCF-7 breast cancer cells were significantly inhibited by Iturin 
A and it induced apoptosis as confirmed by increased Sub G1 populations, DNA fragmentation, 
morphological changes and western blot analysis. Furthermore, Iturin A inhibited EGF induced 
Akt phosphorylation (Ser473 and Thr308) and its downstream targets GSK3β and FoxO3a. Iturin A 
inactivated MAPK as well as Akt kinase leading to the translocation of FoxO3a to the nucleus. Gene 
silencing of Akt in MDA-MB-231 and MCF-7 cells reduced the sensitivity of cancer cells to Iturin A. 
Interestingly, overexpression of Akt with Akt plasmid in cancer cells caused highly susceptible to 
induce apoptosis by Iturin A treatment. In a xenograft model, Iturin A inhibited tumor growth with 
reduced expressions of Ki-67, CD-31, P-Akt, P-GSK3β , P-FoxO3a and P-MAPK. Collectively, these 
findings imply that Iturin A has potential anticancer effect on breast cancer.
The menace of chemo-resistance of the cancer cells and a steady decline in the discovery of new lead 
anticancer molecules has thrown a formidable research challenge to the concerned scientific community. 
One of the most prevalent cancers is breast cancer that is a common malignancy affecting females world-
wide. It is developed due to a number of cellular and molecular transformations that lead to breast cancer 
cell proliferation and inhibition of apoptosis. These events involve disrupting various signaling networks 
and thereby resulting in altered gene expression. Among these deregulated signaling pathways, Akt/PKB 
plays as major contributor to the development of many cancers including breast cancer1,2. A numbers 
of growth factors e.g., epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and 
Insulin-like growth factor (IGF) activate the receptors tyrosine kinase leading to phosphorylation in 
kinase domain. Activated growth factor receptors ultimately induce conversion of phosphatidylinositol 
4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5 trisphosphate (PIP3) in presence of lipid kinase 
phosphoinositide 3-kinase (PI3K). Phosphatase and tensin homolog (PTEN) negatively regulates this 
conversion of PIP2 to PIP3 by phosphatase activity3. Akt remains in cytoplasm in an inactive form, but 
activated Akt translocates to membrane and binds to PIP3. This binding of Akt with membrane lipid 
PIP3 in pleckstrin homology (PH) domain of Akt causes phosphorylation at Thr308 on its activation 
loop by membrane localized 3-phosphoinositide-dependent protein kinase 1(PDK1). Phosphorylation 
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at Ser473 is required for further activation of Akt4. Constitutive activation of Akt, loss of tumor sup-
pressor PTEN, over expression of various growth factor receptors and mutation in PI3K ultimately lead 
to amplification of Akt signaling pathway5–7. Amplified Akt exerts its oncogenic action via triggering 
multiple downstream proteins8. These downstream proteins include Forkhead family of transcription 
factor (FoxO3a) and glycogen synthase kinase 3 (GSK3β ). Akt directly regulates the functions of FoxO3a 
through phosphorylation, leading to its accumulation in the cytoplasm. Inhibition of Akt causes dephos-
phorylation and nuclear localization of FoxO3a, resulting in its activation. Activated FoxO3a triggers 
apoptosis or cell cycle arrest through down regulation of anti apoptotic proteins (Bcl-2, Bcl-xL and 
Mcl-1) via Bim activation9. Another substrate GSK3β (Ser9) induces cell apoptosis via multiple mecha-
nisms10. Altered Akt signaling is well associated with biological events for e.g., tumor cell survival and 
proliferation, inhibition of apoptosis through up regulating Bcl-2 family proteins like Bcl-2, Bcl-xL and 
Mcl-111,12. Changes of BAX conformation as well as translocation of BAX to mitochondria are inhibited 
by Akt leading to suppression of mitochondrial membrane potential change, Cytochrome C release, 
activation of caspase and apoptosis13. So, inhibition of Akt kinase is an attractive target for development 
of new anticancer molecules for breast cancer therapy.
Lipopeptides that are primary metabolites biosynthesized by a number of micro-organisms qualify 
as potential new generation anticancer agents against breast cancer, because of their low toxicity, easy 
biodegradability and their ability to kill the cancer cells selectively through various mechanisms of inhi-
bition of signaling pathways14. Though there are some reports on anticancer activity of surfactin, a well 
known lipopeptide, against breast cancer cell lines15, its hemolytic property and relatively higher toxicity 
are the major bottlenecks16 in the realization of its potential as an anticancer drug. Thus, in the present 
study, we are reporting the anticancer activity of another lipopeptide molecule, Iturin A, purified by us 
from Bacillus megaterium, which is a marine bacterium isolated from the water sample collected from 
the Andaman and Nicobar Islands, India. Although many pharmacological actions of Iturin A have been 
reported, its anticancer property is not yet published in public domain. Our research findings indicated 
that Iturin A induced antiproliferative and apoptotic effect in breast cancer cells in vitro and in vivo. This 
apoptotic effect may be attributed to the inhibition of Akt kinase and its downstream targets FoxO3a 
and GSK3β .
Results
Purification and characterization of lipopeptide. Iturin A present in the culture broth was col-
lected and extracted with methanol. The methanolic extracts were subjected to further HPLC analysis. 
Generally, microorganisms produce lipopeptides as isoforms, which differ in the fatty acid chain length 
and peptide part. In the current work, HPLC chromatogram of methanol extract showed the presence 
of two distinct groups of isoforms. The isoforms of standard Iturin A were eluted between 34–40 min 
(Fig. 1A). The elution time of standard Iturin A matched with that of first group of isoforms from the 
methanol extract, which indicated that this group consisted of Iturin A family of lipopeptides (Fig. 1A). 
This was further corroborated by ESI mass spectrometry analysis of the collected fractions. The mass 
spectral analysis of HPLC fractions showed the presence of molecules in the range of m/z 1043–1093 Da 
(Fig.  1D). These peaks differ by 14 Da, indicating a series of isoforms with different fatty acid chain 
length. C14–C16 Iturin A isoforms were detected as both H+ (1043–1071) and Na+ (1065–1093) adducts, 
respectively. The mass spectra were found to be identical with that of the commercially available Iturin 
A (Fig. 1C). As evident from ESI-MS analysis, this group belonged to Iturin A homologues. The other 
group was identified as fengycin class of lipopeptides. However, C16 Iturin A fraction was used for further 
studies (Fig. 1B). Structurally, Iturin A consists of a hydrophilic peptide moiety containing amino acids 
with conserved sequence (Asn-Tyr-Asn-Gln-Pro-Asn-Ser) linked to a hydrophobic fatty acid chain17 
(Fig. 2A). This lipopeptide is synthesized non ribosomally in various Bacillus species18.
Iturin A retards cell proliferation and promotes apoptosis in breast cancer cells. The 
anti-proliferative action on breast cancer cells was determined by MTT assay. MDA-MB-231 and MCF-7 
cells were treated with 0–20 μ M of Iturin A as well as T47D and MDA-MB-468 cells were treated with 
0–40 μ M of Iturin A for 48 h. The IC50 (50% inhibitory concentration) values of MDA-MB-231, MCF-7, 
MDA-MB-468 and T47D cells were 7.98 ± 0.19, 12.16 ± 0.24, 13.30 ± 0.97 and 26.29 ± 0.78 μ M respec-
tively (Fig. 2B). MDA-MB-231 and MCF-7 cells were selected for further study as they were highly sen-
sitive to Iturin A. Next, we performed flow cytometry, cell cytoskeleton analysis and DNA ladder assay 
to check apoptotic effect of Iturin A in breast cancer cells. Cell cycle analysis revealed time dependent 
increment of Sub G1 population in treated MDA-MB-231 and MCF-7 cells (Fig.  2C,  D). But, no sig-
nificant changes of Sub G1 population were observed in normal HMEC and HaCaT cells (Fig. 2C, D). 
Cytoskeleton remodeling was observed in Iturin A treated MDA-MB-231 and MCF-7 cells (Fig.  2E). 
Interestingly, no significant morphological changes occurred in HMEC and HaCaT cells (Fig.  2E). 
Noticeable DNA ladders were observed in Iturin A treated MDA-MB-231 and MCF-7 cells (Fig. 3A).
Iturin A alters expression profile of proteins involved in apoptosis. Apoptosis is tuned by a 
fine balance between survival proteins and apoptotic proteins. According to our study, Iturin A caused 
significant changes in expresion level of various proteins involed in apoptosis (Fig. 3B, C, D). Sequential 
activation of caspase plays a critical role in final steps of apoptosis. Iturin A treated groups showed 
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prominent decrease of Procaspase3 expression in MDA-MB-231 cells in a time depemdent manner. 
Procaspase7 expression was also reduced in Iturin A treated MDA-MB-231 and MCF-7 cells indicat-
ing the involvement of caspase in Iturin A induced apoptosis. Cleavage of PARP (Poly ADP ribose 
polymerase) and release of Cytochrome C were also observed in treated groups. Further, proapoptotic 
BAX was upregulated as well as anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1 were downregulated in 
MDA-MB-231 and MCF-7 cells treated with Iturin A in time dependent manner.
Iturin A interferes Akt Phosphorylation and its downstream targets. Phospho specific western 
blot analysis indicated that Iturin A caused sharp down regulation of EGF induced phosphorylation of 
Akt (Ser473 and Thr308) and its downstream proteins GSK3β and FoxO3a in treated groups without 
altering total proteins in both cell lines (Fig. 4A, B, C). We also observed that Iturin A inhibited basal 
level (Control) as well as EGF induced expression of all phospho proteins in both cells. Moreover sig-
nificant inhibition of P-MAPK was also observed in Iturin A treated MDA-MB-231 and MCF-7 cells 
(Fig. 4).
Modulation of Akt activity with transfections influences sensitivity of breast cancer cells to 
Iturin A. To verify the involvement of Akt kinase in Iturin A induced cell death, pcDNA-Akt plasmid 
and signal silence® siRNA-Akt were stably transfected in MDA-MB-231 and MCF-7 cells. Western blot 
analysis demonstrated increase phosphorylation status of Akt in pcDNA-Akt transfected groups compare 
to controls and pcDNA groups. In contrast, phosphorylation status of Akt was sharply reduced in siRNA 
transfected groups in breast cancer cells (Fig. 5). Iturin A treatment caused significant Akt inhibition in 
non transfected cells as well as pcDNA-Akt transfected cells. Further, Iturin A caused enhanced inhibi-
tion of Akt in siRNA transfected groups. Similar kinds of results were also found in P-MAPK expression 
(Fig. 5).
Figure 1. Reversed-phase HPLC chromatograms and ESI-MS analysis of the lipopeptides. (A) Standard 
Iturin A procured from Sigma. (B) Crude methanolic extract from the acid-precipitated supernatant fluid of 
Bacillus megaterium. HPLC conditions: Column, Zorbax C18; Mobile phase, milli-Q water and acetonitrile 
with 0.1% TFA; Flow rate, 0.4 ml min−1; Detection, 210 nm. (C) ESI-MS analysis of standard Iturin A 
procured from Sigma. (D) ESI-MS analysis of Group I lipopeptide cluster purified by reversed-phase HPLC. 
ESI-MS conditions: capillary voltage, 35 V; spray voltage, 4.5 kV; capillary temperature, 300 °C.
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Quantitative apoptotic effect of Iturin A was determined by flow cytometry in different transfected 
and non-transfacted groups (Fig. 6A, B). Non transfected and pcDNA (empty vector) transfected groups 
displayed 49.41% and 54.64% Sub G1 fractions in Iturin A treated MDA-MB-231cells (Fig.  6A). Iturin 
A treated MCF-7 cells also showed 43.3% and 44.04% Sub G1 fractions in non transfected and pcDNA 
transfected cells respectively (Fig.  6A). Interestingly, Iturin A treated pcDNA-Akt transfected groups 
exhibited enhanced Sub G1 fractions 83.25% and 69.4% in both cell lines (Fig. 6A). However, only 26.64% 
and 29.86% Sub G1 fractions were observed in siRNA-Akt transfected groups of treated MDA-MB-231 
and MCF-7 cells.
Iturin A inhibits Akt kinase activity in breast cancer cells. Akt kinase assay based on nonradi-
oactive method offers the measurement of kinase activity in the cells. This assay was performed using 
protein extract of MDA-MB-231 and MCF-7 cells treated with Iturin A. Our results showed significant 
dose dependent downregulation of P-GSK3β expression in treated groups compared to controls. These 
results reflected the Akt inhibitory effect of Iturin A in both cell lines (Fig. 6C, D).
Figure 2. Iturin A inhibits proliferation of breast cancer cells. (A) Chemical structure of Iturin A consists 
of peptide chain containing seven amino acids linked to a fatty acid component. (B) MDA-MB-231, MCF-
7, MDA-MB-468 and T47D breast cancer cells are treated with different concentration of Iturin A for 48 h. 
Following drug exposure, MTT solution is added and cells are incubated for 4 h. 100 μ l DMSO was added 
after discarding MTT solution. Dissolved formazan is determined spectrophotometrically to measure the cell 
viability in treated groups compared to control. (C) Breast cancer cells are treated with IC50 dose of Iturin A 
and normal cells are treated with higher dose of IC50 dose of breast cancer cells. Representative histograms 
of MDA-MB-231, MCF-7, HMEC and HaCaT cells and their cell-cycle distribution after 12, 24 and 48 h of 
treatment are shown. (D) Graphical representation of Sub G1 populations (% of Apoptotic cells) in different 
cell lines from flow cytometric analysis. (E) Fluorescence microscopic analysis of treated MDA-MB-231 and 
MCF-7 cancer cells as well as HMEC and HaCaT normal cells (20 × magnification). Values are mean ± S.D 
of three independent experiments. Significance level is represented by *P< 0.05, **P< 0.01, ***P< 0.001.
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Iturin A causes nuclear localization of FoxO3a in breast cancer cells. FoxO3a is a downstream 
protein of Akt signaling pathway. FoxO3a acts as tumor suppressor through inducing apoptosis and cell 
cycle arrest. Activation of Akt leads to shifting of FoxO3a from nucleus to cytoplasm as well as inhibi-
tion of transcriptional activity of it19. We investigated cellular localization of FoxO3a in MDA-MB-231 
and MCF-7 cells in response to Iturin A treatment. It was observed that FoxO3a was mostly present in 
cytoplasm in EGF exposed groups. Translocation of FoxO3a to nucleus from cytoplasm was observed in 
Iturin A treated groups (Fig. 6E). These results suggested that Iturin A induced nuclear accumulation of 
FoxO3a to mediate apoptosis in MDA-MB-231 and MCF-7 cells.
In vivo antitumor effect of Iturin A in MDA-MB-231 mouse xenografts model. Antitumor 
effect of Iturin A was tested on in vivo MDA-MB-231 xenograft model in nude mouse. After four weeks 
of treatment, there was significant reduction in tumor mass and tumor volume in treated groups com-
pared to untreated controls (Fig.  7A,  B,  C). Visible toxicity in each mouse was not found during the 
period of study. Immunohistochemistry of tumor tissue sections showed increase in TUNEL positive 
cells and reduced expression of Ki-67 suggesting in vivo apoptotic and antiproliferative effect of Iturin A 
(Fig. 7D). Decrease phosphorylation of Akt (Ser473 and Thr308), GSK3β , FoxO3a and MAPK was also 
Figure 3. Iturin A induces apoptosis as measured by DNA laddering and western blot analysis. (A) DNA 
fragmentation by agarose gel electrophoresis in MDA-MB-231 and MCF-7 cells treated with Iturin A. (B) 
Western blot analysis of proapoptotic and anti-apoptotic proteins in MDA-MB-231 and MCF-7 cells treated 
with Iturin A for 12, 24 and 48 h. Blots were cut and cropped according to the molecular weight of the 
proteins. (C) and (D) Densitometric plot of proapoptotic and antiapoptotic proteins of MDA-MB-231 and 
MCF-7 cells treated with Iturin A. Each bar represents average arbitrary pixel of three experiments.
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observed in treated groups by immunohistochemical analysis of tumor tissue sections (Fig. 7D, E). But 
expression of total proteins was unaltered.
Discussion
Marine microorganisms currently represent a diverse and unexplored bioresources of valuable bioactive 
molecules. Among these bioactive molecules, lipopeptides show great promise in the development of the 
new chemotherapeutic agents. Previously, we have systematically reviewed the potential role of a num-
ber of lipopeptides e.g., surfactin, somacystinamide A, fengycin, pseudofactin, apratoxin and rakicidin 
Figure 4. Iturin A inhibits Akt signaling pathway. (A) Phosphorylation levels of Akt (Ser473 and Thr308), 
GSK3β , FoxO3a and MAPK (p44/42) are estimated along with corresponding total proteins expression in 
cells grown in serum-free medium and cells stimulated with recombinant human EGF (25 ng/ml) for 30 min 
alone and in the presence of Iturin A. Blots were cut and cropped according to the molecular weight of 
the proteins. (B) Graphical representation of phosphorylation level of Akt, GSK3β , FoxO3a and MAPK in 
treated MDA-MB-231 cells. (C) Graphical representation of phosphorylation level of Akt, GSK3β , FoxO3a 
and MAPK in treated MCF-7 cells. Data are represented as mean ± S.D of three independent experiments. 
Significance level is represented by *P< 0.05, **P< 0.01, ***P< 0.001.
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as new generation anticancer agents20. In the current study, we isolated and purified Iturin A which is 
a lipopeptide molecule. This lipopeptide was reported to possess anti-fungal property against variety of 
fungi21. However, its anticancer property was not reported earlier. The aim of present study was to inves-
tigate in vitro and in vivo anticancer activity of Iturin A. Our study also demonstrated possible molecular 
mode of actions in Iturin A induced apoptosis in breast cancer.
Isoforms of Iturin A produced by marine Bacillus megaterium was purified by RP-HPLC and purity 
level of the isoforms was confirmed by comparing with that of the standard Iturin A from Sigma Aldrich, 
St. Louis, MO, USA. The isoform containing longer fatty acid chain was selected for further pharmaco-
logical studies as it effectively interacts with the cell membrane22.
The MTT assay is a colorimetric assay to determine cell cytotoxicity of anticancer molecules. 
This assay revealed dose dependent cytotoxic effects of Iturin A against different breast cancer cells 
MDA-MB-231, MCF-7, T47D and MDA-MB-468 (Fig. 2B). Iturin A showed more potent cytotoxic action 
on MDA-MB-231 and MCF-7 cells compared to other cell lines. Iturin A caused prominent morpho-
logical changes like membrane blebbing, loss of lamellipodia/filopodia and cellular shrinkage (Apoptotic 
features) in treated MDA-MB-231 and MCF-7 cells but no significant effects in normal HMEC and 
HaCaT cells (Fig. 2E). Further, Sub G1 accumulation of apoptotic cells was observed following treatment 
with Iturin A with different time points (Fig. 2C and D). Interestingly, human mammary epithelial cells 
HMEC and normal keratinocyte HaCat showed insignificant Sub G1 accumulation corroborating with 
Figure 5. Transfection study. (A) MDA-MB-231 and MCF-7 cells are transfected with pcDNA, pcDNA-Akt 
and siRNA-Akt following Iturin A treatment. Expression levels of P-Akt (Ser 473 and Thr 308) and P-MAPK 
are evaluated by immunoblotting. β -Actin is used as loading control. Blots were cut and cropped according 
to the molecular weight of the proteins. (B) and (C) Densitometric plot of P-Akt (Ser 473 and Thr 308) and 
P-MAPK levels in both cell lines. Each bar represents mean ± S.D from three different experiments.
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morphological study of normal cells (Fig.  2C  and  D). All these data indicated selective cytotoxic and 
apoptotic effect of Iturin A on breast cancer cells.
DNA fragmentation is a hallmark of apoptosis caused by activation of endogenous endonucleases 
followed by cleavage of chromatin DNA. Prominent ladders formation indicated presence of fragmented 
DNA reflecting the involvement of apoptosis in Iturin A treated groups of MDA-MB-231 and MCF-7 
cells (Fig. 3A).
Next, we performed western blot analysis to assess the profile of various pro and anti-apoptotic 
proteins as these proteins are regulated by Akt signaling11,12. Our finding showed downregulation of 
anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1 as well as upregulation of apoptotic protein BAX in 
Iturin A treated MDA-MB-231 and MCF-7 cells (Fig. 3B, C, D). Our study described that elevated BAX 
to Bcl-2 ratio exerted apoptotic effect through mitochondrial Cytochrome C release, leading to activation 
of caspase3/7, PARP cleavage and DNA fragmentation. So, caspase dependent cell death was involved in 
apoptosis mediated by Iturin A on breast cancer cells.
It is now established that abnormal activation of Akt kinase is involved in many cancers including 
breast cancer23. So, targeting Akt kinase is a great promise for anticancer drug discovery. A number of 
compounds e.g. Perifosine, Erufosine, KP372-1, Triciribine, GSK690693 and MK2206 have been reported 
to target Akt signaling pathway for their anticancer actions6. Here, we investigated that whether Iturin 
Figure 6. Cell cycle analysis of transfected cells, in vitro Akt kinase assay and translocation study of 
FoxO3a. (A) Flow cytometric analysis of transfected cells is performed to measure Sub G1 population. 
Transfected cells are treated with IC50 dose of Iturin A for 48 h and subjected to cell cycle analysis after 
staining with propidium iodide. (B) Graphical representations of Sub G1 population from flow cytometric 
analysis. (C) In vitro Akt kinase assay is performed using GSK3 fusion protein according to manufacture 
protocol. Blots were cut and cropped according to the molecular weight of the proteins. (D) Densitometric 
analysis of P-GSK3β level from kinase assay. Each bar represents mean ± S.D from three different 
experiments. Significance level is represented by *P< 0.05, **P< 0.01, ***P< 0.001. (E) Breast cancer cells 
are treated by Iturin A with respective IC50 doses for 48 h. Florescent images are taken after incubation with 
primary antibody followed by FITC tagged secondary antibody. P-FoxO3a is found mostly in cytoplasm in 
EGF treated cancer cells. Iturin A treatment causes nuclear accumulation of P-FoxO3a in both cell lines. 
Florescent images are taken at 20 × magnification.
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A could inhibit Akt leading to apoptosis. Interestingly, current study revealed that Iturin A inhibited 
phosphorylation of Akt at both sites (Ser 473 and Thr308) in MDA-MB-231 and MCF-7 cells (Fig. 4). 
Next we assessed the inhibitory effect of Iturin A on Akt kinase activity by nonradioactive kinase assay 
kit in cell free system. This assay for in vitro measurement of Akt kinase activity showed diminished 
phosphorylation of fusion protein GSK in Iturin A treated breast cancer cells. This phenomenon reflected 
the inhibitory effect of Iturin A on Akt kinase (Fig.  6C,  D). After that we hypothesized that Iturin A 
could inhibit phosphorylation state of Akt substrates FoxO3a and GSK3β to confirm Akt inhibition. 
FoxO3a is a downstream protein and forkhead family of transcription factors of Akt signaling pathway. 
Activated Akt phosphorylates FoxO3a and prevents apoptotic effects of FoxO3a by inhibiting nuclear 
accumulation. FoxO3a acts as tumor suppressor by inducing apoptosis and cell cycle arrest. So, Akt 
inhibition indirectly may cause reactivation and nuclear export of FoxO3a24. Our results confirmed 
that phosphorylation of FoxO3a was decreased after Iturin A treatment without altering total proteins 
(Fig. 4). Next, we assessed nuclear accumulation study of FoxO3a in Iturin A treated breast cancer cells. 
FoxO3a, when it is activated accumulates in nucleus and initiates transcriptional activity25. Our study 
demonstrated that Iturin A caused nuclear accumulation of FoxO3a in Iturin A treated MDA-MB-231 
and MCF-7 cells. Iturin A suppressed Akt activity and indirectly inhibited phosphorylation of FoxO3a 
(Fig. 6E). Our results are similar to the previous report that reduction of FoxO3a phosphorylation level 
and nuclear localization were indirectly caused by paclitaxel mediated inhibition of Akt26. Another Akt 
Figure 7. Anti-tumor activity of Iturin A in MDA-MB-231 human breast cancer xenografts. Nude mice 
bearing MDA-MB-231 xenografts treated with Iturin A (5 and 10 mg/kg). (A) Tumor bearing nude mice and 
excised tumors at the end of experiment. (B, C) Excised tumor volume (mm3) and mass (gm) are shown by 
representative bar graph. Significance level is represented by *P< 0.05, **P< 0.01, ***P< 0.001. (D) TUNEL 
assay and immunohistochemistry of Ki-67, CD-31, P-Akt (Ser 473 and Thr 308) and T-Akt are performed 
from excised tumors tissue samples. (E) Immunohistochemitry of P-GSK3β , T-GSK3β , P-FoxO3a, T-FoxO3a, 
P-MAPK and T-MAPK.
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substrate GSK3β is negatively modulated by Akt activity. Activated GSK3β (Non phosphorylated state) 
is reported to regulate cell cycle analysis and apoptosis27. Akt prevents the apoptotic activity of GSK3β 
by phosphorylating it. Our results suggested that Iturin A inhibited Akt activity and their by indirect 
inhibition of its substrate P-GSK3β (Fig. 4). In addition, transfection study provided the validation that 
Iturin A could suppress Akt kinase activity and block its signaling pathway in vitro. Increase activ-
ity of Akt was detected in pcDNA-Akt plasmid transfected groups and reduced expression of Akt was 
detected in siRNA-Akt transfected cells (Fig. 5). Iturin A treatment inhibited expression of Akt in both 
transfected and non-transfected groups of MDA-MB-231 and MCF-7 cells. Enhanced apoptotic effects 
were observed in Iturin A treated MDA-MB-231 and MCF-7 cells stably transfected with Akt plasmid. 
Interestingly, reduced apoptotic effects were observed in Iturin A treated breast cancer cells transfected 
with siRNA-Akt (Fig. 6A, B). These results are similar to the effect of another Akt inhibitor, triciribine 
which inhibits Akt over expressing cells more potently than those low Akt expressing cells28. So, apop-
totic effects of Iturin A depend on Akt activity in cancer cells.
The present study also reported in vivo antitumor activity of Iturin A on nude mice transplanted with 
MDA-MB-231 cells. Tumor volume, mass and expression of various proteins were measured to assess 
antitumor property of Iturin A (Fig.  7A, B, C). Our study demonstrated markedly reduction of tumor 
volume and mass in a dose dependent fashion. TUNEL assay displayed presence of DNA fragmentation 
(TUNEL positive cells) in tumor tissue section of Iturin A treated groups (Fig. 7D). Immunohistochemical 
staining of tumor tissue indicated that Ki-67 and CD-31 expression were reduced in Iturin A treated 
groups compared to untreated controls. All these findings indicated in vivo antiproliferative and apop-
totic potential of Iturin A in mouse xenografts model. Further, we investigated expression of Akt and 
its downstream proteins by immunohistochemical analysis. Reduced expression of P-Akt (Ser473 and 
Thr308) and its downstream substrates P-GSK3β and P-FoxO3a (Fig. 7D, E) was observed in Iturin A 
treated groups. Phosphorylation of MAPK was also inhibited in Iturin A treated groups (Fig. 7E).
In conclusion, the current study suggested that Iturin A of marine bacterial origin could inhibit Akt 
signaling network leading to apoptosis induction in breast cancer cells. This agent also inhibited tumor 
growth in breast cancer xenograft model. Our results also validated the discovery of Iturin A for therapy 
of breast cancer with elevated level of Akt. These results of the preclinical studies are very encouraging 
and promising for the clinical development of an Iturin A mediated Akt inhibitory mechanism based 
therapy for breast cancer in the near future.
Materials and methods
Chemicals and Reagents. For immunoblot and immunohistochemical analysis, various antibodies 
like rabbit monoclonal anti-p-MAPK, anti-MAPK, anti-p-Akt (Ser & Thr) and anti-Akt, anti-p-GSK-3β , 
anti-GSK-3β , anti-p-FoxO3a, anti-FoxO3a monoclonal mouse anti-CD-31, rabbit anti-caspase 3/7 were 
purchased from Cell Signaling Technology, Beverly, MA, USA. Mouse anti-Ki-67, rabbit monoclo-
nal anti-PARP, mouse monoclonal anti-Bcl-2, anti-Bax, anti-Mcl-1, anti-Bcl-xL, HRP conjugated goat 
anti-rabbit IgG and goat anti-mouse IgG were purchased from Santa Cruz Biotechnology, Santa Cruz, 
CA, USA. Mouse monoclonal anti-β -actin and other reagents were procured from Sigma Aldrich, St. 
Louis, MO, USA. Antibodies dilutions have been made as per the manufacturer’s instruction. The pcD-
NA3-Akt-HA plasmid was obtained as gift sample from Dr. Guy Salvesen (University of California, 
San Diego, CA, USA). siRNA Akt and pcDNA3.1(-) were purchased from Cell Signaling Technology, 
Beverly, MA, USA and Invitrogen, USA respectively. Opti-MEM®I Reduced Serum Media and fetal 
bovine serum (FBS) were purchased from Gibco-BRL Invitrogen Corporation, CA, USA. FuGENE® HD 
transfection reagent was obtained from Roche Applied Science, Mannheim, Germany. Trypsin, Bovine 
serum albumin (BSA) and antibiotics (10,000 U/L penicillin and 10 mg/L streptomycin) were purchased 
from Himedia, Mumbai, India.
Microorganism, media composition and culture conditions. A marine bacterium Bacillus meg-
aterium was used for production of Lipopeptide29. This bacterial strain was obtained from sea water of 
the Andaman and Nicobar Islands, India. For preparation of the primary inoculums, bacterial strain 
was maintained in Zobell marine agar (Himedia, Mumbai, India) and grown in Zobell marine broth 
following incubation for 12 h at 32 °C. Primary inoculums were inoculated in 250 ml Erlenmeyer flask 
containing glucose mineral salts medium (GMSM containing: glucose− 25 g/L, NH4NO3–6 g/L, KH2PO4–
0.028 g/L, K2HPO4–1.6 g/L, MgSO4•7H2O–0.3 g/L and CaCl2•2H2O–0.2 g/L) and the flask was kept in a 
shaking incubator at 180 rpm and 32 °C till mid-exponential growth of cells. The inoculum was further 
inoculated in 1 L Erlenmeyer flasks containing 200 ml GMSM and kept in incubator at 180 rpm and 
32 °C. Fermentation broth samples were collected at different time for lipopeptide collection.
Cell lines and culture condition. Human breast cancer cell lines MDA-MB-231, MDA-MB-468, 
MCF-7, T47D and keratinocytes HaCaT were purchased from National Centre for Cell Science (NCCS), 
Pune, India. Human mammary epithelial cells (HMEC) were purchased from Lonza Clonetics, San 
Diego, USA and cultured in recommended medium. Other cells were grown in Dulbecco’s modification 
of Eagle’s medium (DMEM) supplemented with 3.7 g Sodium bicarbonate (Invitrogen Corporation, CA), 
antibiotics (10,000 U/L penicillin and 10 mg/L streptomycin) (Himedia, Mumbai, India) and 10% FBS. 
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Adherent monolayer cell lines were maintained in plastic culture flask and incubated at 37 °C in 5% CO2 
in humidified incubator.
Isolation of marine bacterial lipopeptide. Iturin A produced by Bacillus megaterium was iso-
lated according to earlier method30. After 28 h of cultivation, the cells were separated by centrifugation. 
Concentrated HCl was added in the culture broth to reduce the pH (up to 2.0).The precipitate was 
taken by centrifugation and extracted with methanol. Further analysis was performed with concentrated 
methanolic extracts.
Purification and characterization of lipopeptide. The extract was purified using reverse phase 
HPLC instrument (Agilent technologies, CA, USA) equipped with Zorbax C18 column and photodi-
ode array detector. The mobile phase was consisted of solvent A (MilliQ water) and solvent B (HPLC 
grade acetonitrile with 0.1% trifluoroacetic acid). The lipopeptides were eluted by linearly increasing the 
percentage of solvent B from 5–95% for 60 min at a flow rate of 0.4 ml/min. About 50 μ l of methanol 
extracted sample and standard Iturin (Sigma, USA) was injected into the column. The HPLC fractions 
were collected automatically and subjected to mass spectrometry. Electrospray ionization mass spectrom-
etry (ESI-MS) analysis was performed on EVOQ triple quadrupole mass spectrometer (Bruker). ESI-MS 
conditions were as follows: capillary voltage of 35 V, a spray voltage of 4.5 kV and a capillary temperature 
of 300 °C. Samples were injected with a syringe at a flow rate of 0.2 ml/min.
Cell cytotoxicity assay of Iturin A. Iturin A fraction was collected from HPLC analysis, dried and 
dissolved in milliQ water (pH adjusted to 7.4) and stored at − 20 °C. The stock solution was diluted in 
incomplete medium just before use. Cell cytotoxicity assay was performed by using MTT dye according 
to previous method31. MDA-MB-231, MDA-MB-468, MCF-7 and T47D cells were seeded in 96 well plate 
(2.5 × 103 cells/well) and kept in incubator for 24 h to attach cells. After that, breast cancer cells were 
treated with different concentrations of Iturin A. Following 48 h of treatment, 100 μ l of MTT solution 
(1 mg/ml in DMEM) was added in each well and the plates ware incubated for another 4 h at 37 °C. 
MTT dye is converted to purple formazan crystal due to mitochondrial reductase activity of live cells. 
The formazan crystal was dissolved in 100 μ l Dimethyl sulfoxide (DMSO) per well and optical density 
was measured by microplate reader (Bio-Rad, Hercules, CA, USA) at 540 nm. Due to higher sensitivity, 
MDA-MB-231 and MCF-7 cells were chosen for further study.
Flow cytometry based apoptosis assay. Apoptotic effects of Iturin A on the MDA-MB-231, MCF-
7, HMEC and HaCaT cells were determined using flow cytometry analysis by previous method32. Briefly, 
2.0 × 104 cells/well were seeded in a 6-well plate and incubated for 24 h for cell growth. Incomplete 
medium was added in 6-well plate and it was kept in incubator overnight for starvation following time 
dependent (12, 24 and 48 h) treatment of Iturin A. After treatment, cells were collected by trypsinization 
and fixed with chilled ethanol. Following overnight fixation, cells were centrifuged and washed with PBS 
followed by propidium iodide staining. The cells were analyzed by flow cytometry.
Cytoskeletal analysis by fluorescence microscopy. MDA-MB-231, MCF-7, HMEC and HaCaT 
cells were seeded on sterile lysine coated cover slips. Cells were treated with Iturin A for 12, 24 and 
48 h. Adherent monolayer cells were washed with PBS and fixed with 4% paraformaldehyde. Cells were 
washed with PBS and permeabilized with 0.1% triton X-100 for 1 min. Rhodamine phalloidin staining 
was performed to visualize cell cytoskeleton. DAPI was used to stain nucleus. After staining, the adhering 
cells were washed three times with PBS, dried and mounted on slides. Fluorescent images were captured 
under a Zeiss Observer Z1 microscope (Carl Zeiss, Germany) at 20 × magnification33.
DNA ladder assay. MDA-MB-231 and MCF-7 cells were treated with Iturin A for 12, 24 and 48 h 
along with control cultures in serum free medium34. Both suspended and adherent cells were collected 
and washed with PBS. Then cells were lysed by lysis buffer. After that, total DNA was isolated by DNA 
isolation kit (Sigma Aldrich, St. Louis, MO, USA). DNA fragmentation was checked by agarose gel 
electrophoresis.
Western Blot Analysis. MDA-MB-231 and MCF-7 cells were seeded in 6-well plates with subsequent 
treatment with IC50 dose of Iturin A for 12, 24 and 48 h to check the expression of proteins involved in 
apoptosis. To evaluate expression of phospho proteins, cells were treated with Iturin A and stimulated 
by human recombinant protein EGF (25 ng/ml) for 30 min. Both suspended cells as well as adherent 
cells were collected and washed with PBS twice. Cells were lysed with NP-40 lysis buffer (Invitrogen 
Corporation, CA, USA). After that, western blot analysis was performed according to previous reported 
methods35.
Akt kinase assay. The activity of Akt kinase was estimated by using Akt Kinase assay kit (Cell 
Signaling Technology, Beverly, MA, USA) according to manufacturer’s protocols. MDA-MB-231 and 
MCF-7 cells were treated with different doses of Iturin A for 12 h and Akt kinase activity was measured 
according to earlier reported method36.
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Transfection study. MDA-MB-231 and MCF-7 cells were plated in 70 mm Petri dishes in complete 
medium. Cells were starved for overnight with serum free medium. Cells were transiently transfected 
with 5 μ g of pcDNA-Akt and empty vector with 7.5 μ l of FuGENE® HD transfection reagent in 100 μ l 
of Opti-MEM®I reduced serum media according to manufacturer’s protocol. After 24 h of transfection, 
the cells were treated with Iturin A for 24 h in serum free medium. siRNA-Akt was used to silence 
Akt expression. Briefly, cells were seeded in 70 mm Petri plates. After 70% confluency, cells were trans-
fected with 14 mM siRNA-Akt in 6 μ l DharmaFECT 4 Transfection Reagent (Thermo scientific) and 1 ml 
Opti-MEM®I reduced serum media according to manufacturer’s protocol. After 24 h of transfection, cells 
were treated with Iturin A for 24 h in serum free medium. After Iturin A treatment, both pcDNA-Akt 
and siRNA-Akt transfected cells were lysed with NP-40 lysis buffer and the protein expression pro-
files were checked by immunoblotting as discussed before. ImageMaster 2D Platinum 7.0 Software (GE 
Healthcare Life Sciences, NJ, USA) was used to plot comparative densitometric graph of blots. Iturin A 
treated transfected as well as control cells were also analyzed by flow cytometry for detection of apoptosis 
as per above described method35.
Immunofluorescence staining for FoxO3a localization in breast cancer cells. To study nuclear 
accumulation of FoxO3a protein, indirect immunoflorescence assay was performed. Briefly, cells were 
grown on sterile lysine coated cover slips following treatment with Iturin A or EGF. Cell fixation was 
performed using 4% paraformaldehyde for 30 min and cells were permeabilized with 0.1% Triton X-100 
solution for one minute. Cover slips were blocked with 5% BSA for one hour to remove non-specific 
bindings. Samples were incubated in primary antibody with appropriate dilution for overnight at 4 °C. 
Samples were incubated for 1 h in dark with FITC (Fluorescein isothiocyanate) tagged secondary anti-
body (Dako) after three times washing with PBST. Propidium iodide was used for nuclear staining. 
After drying, cover slips were mounted with D.P.X. and fluorescent images were captured under a Zeiss 
Observer Z1 microscope at 20 × magnification37.
Inhibition of tumor in human breast cancer xenograft mouse model. In vivo antitumor activity 
of Iturin A was studied using human breast cancer nude mouse xenograft model. This study was approved 
by ministry of earth science (MOES), India; under the project number MOES/16/48/09/RDEAS. Animal 
experiment was carried out in accordance with the approved guidelines of Indian Council of Medical 
Research (ICMR), New Delhi, India. All experiment protocols were approved by institutional animal eth-
ical committee of Indian Institute of Technology Kharagpur, India. Mice were maintained in aseptic con-
dition at institute animal facility for seven days before injection with MDA-MB-231 cells. MDA-MB-231 
cells (2 × 106 cells in matrigel) were injected subcutaneously in 6–7 week old female athymic BALB/c 
(nu+ /nu+ ) mice. Tumors were developed after 14 days and animals were randomly divided in three 
groups (Each group contains five animals) followed by measurement of tumor volume and body weight. 
Iturin A was injected by tail vein as following manner: (I) group1-control, (II) group2-Iturin A 5 mg/kg 
and (III) group 3-Iturin A 10 mg/kg. Animals were treated for four weeks in alternative days. Animals 
were observed regularly for tumor growth, survival, visible toxicity and changes in body weight during 
the study. After treatment, all animals were sacrificed to measure tumor volume and tumor weight. 
Tumor sections were fixed in formalin for immunohistochemical analysis38.
TUNEL and immunohistochemistry of tissue sections. The apoptotic effect of Iturin A in mice 
tumor was evaluated by using commercial TUNEL kit (Roche) according to manufacturer’s protocols. 
Propidium iodide was used as counter stain. Immunohistochemistry for a number of proteins (Ki-67, 
P-Akt, T-Akt, P-GSK3β , T-GSK3β , P-MAPK and T-MAPK) was also performed by previous methods31.
Software and Statistical analysis. GraphPad prism software was used to perform statistical analy-
sis. Each experiment was carried out at least three times. The results with p-value< 0.05 were considered 
significant. Image Master 2D Platinum 7.0 Software (GE Healthcare Life Sciences, NJ, USA) was used for 
densitometry analysis of blot. All data were represented as mean ± standard deviation (SD).
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